

CURRICULUM VITAE

Bum Jun Kim, M.D., Ph.D.

Division of Hematology-Oncology, Department of Internal Medicine, Hallym University
Medical Center, Hallym University College of Medicine

Address (Work)

Division of Hematology-Oncology, Department of Internal Medicine, Hallym
University Medical Center, Hallym University College of Medicine, Anyang-si,
Gyeonggi-do 14068, Republic of Korea

Tel: +82-31-380-3704, Fax: +82-31-380-1528

E-mail: getwisdom1025@gmail.com (personal e-mail)

getwisdom1025@hallym.or.kr (institutional e-mail)

Education

2004. 3 – 2006. 2	Pre-Medicine
	Hallym university college of medicine
	Chuncheon-si, Gangwon-do, Republic of Korea
2006. 3 – 2010. 2	M.D.
	Graduate summa cum laude
	Hallym university college of medicine
	Chuncheon-si, Gangwon-do, Republic of Korea

2013. 9 – 2017.2 Master's degree
Postgraduate School
Hallym university college of medicine
Chuncheon-si, Gangwon-do, Republic of Korea

2018. 3 – 2020.2 Doctor's degree
Postgraduate School
Hallym university college of medicine
Chuncheon-si, Gangwon-do, Republic of Korea

Graduate Training

2010. 3 – 2011.2 Internship
Hallym University Medical Center,
Anyang-si, Gyeonggi-do, Republic of Korea

2011. 3 – 2015.2 Residency
Internal Medicine, Hallym University Medical Center,
Anyang-si, Gyeonggi-do, Republic of Korea

2015. 3 – 2016.2 Clinical fellowship (Medical Oncology)
Department of Oncology, Asan Medical Center,
University of Ulsan College of Medicine, Seoul,
Republic of Korea

2016. 3 – 2017.2 Clinical fellowship (Hemato-Oncology)

Department of Internal Medicine,

Kangnam Sacred-Heart Hospital,

Hallym University Medical Center,

Hallym University College of Medicine, Seoul,

Republic of Korea

2017. 5 – 2020.4 Medical Officer, Captain

Division of Hemato-Oncology,

Department of Internal Medicine,

National Army Capital Hospital,

The Armed Forces Medical Command,

Sunnam, Republic of Korea

2020. 5 – Assistant professor

Division of Hematology-Oncology,

Department of Internal Medicine,

Hallym University Medical Center,

Hallym University College of Medicine,

Anyang-si, Gyeonggi-do, Republic of Korea

Certification

- | | |
|------|---|
| 2015 | Diploma, Korean Board of Internal Medicine (#15334) |
| 2017 | Diploma, Hemato-oncology Subspecialist (#6-17-548) |

License

- | | |
|------|----------------------------------|
| 2010 | Korean Medical License (#104509) |
|------|----------------------------------|

Affiliation

- Member, Korean Medical Association
- Member, Korean Association of Internal Medicine
- Member, Korean Association of Clinical Oncology
- Member, Korean Cancer Association

Publications in Journals

1st Author

1. Kim BW, Kim YJ, Sohn SH, Kim B, Sul HJ, Kim HS, Zang DH. Tivantinib inhibits the VEGF signaling pathway and induces apoptosis in gastric cancer cells with c-MET or VEGFA amplification. Invest New Drugs. 2020 May 2 [Epub ahead of print]
2. Lee KW, Kim BJ, Kim MJ, Han HS, Kim JW, Park YI, Park SR. A Multicenter Randomized Phase II Study of Docetaxel vs. Docetaxel Plus Cisplatin vs. Docetaxel Plus S-1 as Second-Line Chemotherapy in Metastatic Gastric Cancer Patients Who Had Progressed after Cisplatin Plus Either S-1 or Capecitabine. Cancer Res Treat. 2017; 49: 706–16.
3. Kim BJ, Yoo C, Kim KP, Hyung J, Park SJ, Ryoo BY, Chang HM. Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients. Br J Cancer. 2017; 116: 561–7.

4. Yoo C, Kim BJ, Kim KP, Lee JL, Kim TW, Ryoo BY, Chang HM. Efficacy of Chemotherapy in Patients with Unresectable or Metastatic Pancreatic Acinar Cell Carcinoma: Potentially Improved Efficacy with Oxaliplatin-Containing Regimen. *Cancer Res Treat* 2017; 49: 759–65.
5. Kim BJ, Hyung J, Yoo C, Kim KP, Park SJ, Lee SS, Park DH, Song TJ, Seo DW, Lee SK, Kim MH, Park JH, Cho H, Ryoo BY, Chang HM. Prognostic factors in patients with advanced biliary tract cancer treated with first-line gemcitabine plus cisplatin: retrospective analysis of 740 patients. *Cancer Chemother Pharmacol*. 2017; 80: 209–15.
6. Kim JH, Kim BJ, Kim HS, Kim JH, Kim BJ, Kim HS. Clinicopathological impacts of high c-Met expression in renal cell carcinoma: a meta-analysis and review. *Oncotarget*. 2017; 8: 75478-87.
7. Kim BJ, Kim HS, Jang HJ, Kim JH. Helicobacter pylori Eradication in Idiopathic Thrombocytopenic Purpura: A Meta-Analysis of Randomized Trials. *Gastroenterol Res Pract*. 2018; 2018: 6090878.
8. Kim BJ, Kim JH, Kim HS. Survival benefit of immune checkpoint inhibitors according to the histology in non-small-cell lung cancer: A meta-analysis and review. *Oncotarget*. 2017; 8: 51779–85.
9. Hyung J, Kim BJ, Yoo C, Kim KP, Lee JL, Jung JH, Chang HM, Ryoo BY. Clinical Benefit of Maintenance Therapy for Advanced Biliary Tract Cancer Patients Showing No Progression after First-Line Gemcitabine Plus Cisplatin. *Cancer Res Treat* 2019; 51: 901-9.
10. Kim BJ, Kim JH, Kim HS, Zang DY. Prognostic and predictive value of VHL gene alteration in renal cell carcinoma: a meta-analysis and review. *Oncotarget*. 2017; 8: 13979–85.
11. Kim BJ, Kim JH, Jang HJ, Kim HS, Kim BJ, Kim JH, Jang HJ, Kim HS. The role of anti-EGFR agents in the first-line treatment of advanced esophago-gastric adenocarcinoma: a meta-analysis. *Oncotarget*. 2017; 8: 99033-40.
12. Kim BJ, Kim HS, Kim JH, Lee KY. Moderate to Severe Thrombocytopenia During Pregnancy: A Single Institutional Experience. *Indian J Hematol Blood Transfus*. 2017; 33: 581-85.
13. Kim BJ, Jeong JH, Kim JH, Kim HS, Jang HJ. The role of targeted agents in the adjuvant treatment of colon cancer: a meta-analysis of randomized phase III studies and review. *Oncotarget*. 2017; 8: 31112–8.
14. Kim BJ, Jang HJ, Kim HS, Kim JH. Current Status of Immune Checkpoint Inhibitors in Gastrointestinal Cancers. *J Cancer*. 2017; 8: 1460–5.
15. Kim BJ, Jang HJ, Kim JH, Kim HS, Lee J. KRAS mutation as a prognostic factor in

ampullary adenocarcinoma: a meta-analysis and review. *Oncotarget*. 2016; 7: 58001–6.

16. Kim BJ, Jeong JH, Kim HS, Kim JH, Kim BJ, Jeong JH, Kim HS, Kim JH. The role of anti-EGFR agents in patients with locoregionally advanced head and neck cancer: a meta-analysis of randomized trials. *Oncotarget*. 2017; 8: 102371-80.

Co-author

17. Kim JH, Kim HS, Kim BJ. Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A meta-analysis and review. *Oncotarget*. 2017; 8: 48248–52.
18. Kim JH, Kim HS, Kim BJ, Lee J, Jang HJ, Kim JH, Kim HS, Kim BJ, Lee J, Jang HJ. Prognostic value of c-Met overexpression in pancreatic adenocarcinoma: a meta-analysis. *Oncotarget*. 2017; 8: 73098-104.
19. Kim JH, Kim HS, Kim BJ, Kim JH, Kim HS, Kim BJ. Prognostic value of smoking status in non-small-cell lung cancer patients treated with immune checkpoint inhibitors: a metaanalysis. *Oncotarget*. 2017; 8: 93149-55.
20. Kim JH, Kim HS, Kim BJ, Han B, Choi DR, Kwon JH. Prognostic Impact of TTF-1 Expression in Non-Squamous Non-Small-Cell Lung Cancer: A Meta-Analysis. *J Cancer*. 2018; 9:4279-4286.
21. Kim JH, Kim BJ, Kim HS, Kim JH. Current Status and Perspective of Immunotherapy in Gastrointestinal Cancers. *J Cancer*. 2016; 7: 1599–604.
22. Jang HJ, Kim BJ, Kim JH, Kim HS, Jang HJ, Kim BJ, Kim JH, Kim HS. The addition of bevacizumab in the first-line treatment for metastatic colorectal cancer: an updated meta-analysis of randomized trials. *Oncotarget*. 2017; 8: 73009-16.
23. Kim JH, Kim HS, Kim BJ. Prognostic Value of MET Copy Number Gain in Non-Small-Cell Lung Cancer: An Updated Meta-Analysis. *J Cancer*. 2018; 9:1836-1845.
24. Kim JH, Kim BJ, Jang HJ, Kim HS. Comparison of the RECIST and EORTC PET criteria in the tumor response assessment: a pooled analysis and review. *Cancer Chemother Pharmacol*. 2017; 80: 729-35.
25. Kim JH, Kim HS, Kim BJ, Kim JH, Kim HS, Kim BJ. MET inhibitors in advanced non-small-cell lung cancer: a meta-analysis and review. *Oncotarget*. 2017; 8: 75500-8.
26. Kim JH, Kim HS, Kim BJ, Jang HJ, Lee J, Kim JH, Kim HS, Kim BJ, Jang HJ, Lee J. Prognostic value of c-Met overexpression in hepatocellular carcinoma: a meta-analysis and review. *Oncotarget*. 2017; 8: 90351-7.

Honors and Achievements:

1. Investigator of the year, 2017

National Army Capital Hospital

2. Grand prize, academic award, 2017

Hallym University College of Medicine

Abstracts presented at the international symposiums:

1. European Cancer Congress 2015, Vienna, Austria (poster presentation)

Kim BJ, Lee KW Kim MJ, Han HS, Park YI, Park SR: A multicenter randomized phase II study of docetaxel vs. docetaxel plus cisplatin vs. docetaxel plus S-1 as second-line chemotherapy in metastatic gastric cancer patients who had progressed after cisplatin plus either S-1 or capecitabine

2. The 42nd Annual Meeting of Korean Cancer Association with International Cancer Conference 2016, Seoul, Republic of Korea (oral presentation)

Kim BJ, Yoo C, Kim KP, Lee JL, Kim TW, Ryoo BY, Chang HM: Efficacy of Chemotherapy in Patients with Pancreatic Acinar Cell Carcinoma